Global Osteoarthritis Therapeutics Market Report 2019-2024 | Market Projected to Reach US$ 10.1 Billion by 2024, from US$ 6.8 Billion in 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 8.1%.

  • This report analyzes the osteoarthritis therapeutics market by anatomy, drug type, route of administration, distribution channel, purchasing pattern, and region.
  • Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years.
  • In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.
  • Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Growth in this industry is driven by the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. On the other hand, the availability of alternative non-drug pain management therapies is a major market challenge.

Key players in the osteoarthritis therapeutics market include Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline plc (UK), Bayer AG (Germany), Abbott (US), Pfizer (US), Eli Lilly (US), Anika Therapeutics (US), and Flexion Therapeutics (US).

Knee osteoarthritis segment to witness the highest growth during the forecast period

Based on anatomy, the osteoarthritis therapeutics market is segmented into knee, hip, hand, and small-joint. The knee osteoarthritis segment is projected to grow at the highest CAGR during the forecast period. A large number of patients suffering from knee osteoarthritis is the major factor supporting the growth of this segment.

Viscosupplementation agents segment to register the highest growth in the osteoarthritis therapeutics market during the forecast period

Based on drug type, the osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is sub-segmented into duloxetine and acetaminophen, while the NSAIDs segment is sub-segmented into naproxen, aspirin, diclofenac, ibuprofen, and other molecules. The viscosupplementation agents segment is projected to witness the highest growth in the osteoarthritis therapeutics market during the forecast period. The rising incidence of knee osteoarthritis is one of the major factors supporting the growth of this segment.

Asia Pacific is estimated to register the highest CAGR during the forecast period

In this report, the osteoarthritis therapeutics market is segmented into four major regional segments, namely, Europe, North America, Asia Pacific, and the Rest of the World (RoW). The market in Asia-Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is driven primarily by the rising incidence and prevalence of osteoarthritis, increasing geriatric and obese populations, and healthcare infrastructure improvements in several APAC countries.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the osteoarthritis therapeutics market
  • Product Development/Innovation: Detailed insights on the product approvals, R&D activities, and product launches in the osteoarthritis therapeutics market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the osteoarthritis therapeutics market
  • Market Development: Detailed information about emerging markets. The report analyzes the market for various osteoarthritis therapeutics across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the osteoarthritis therapeutics market

Market Dynamics

Drivers

  • Rapid Growth in the Geriatric and Obese Populations and the Associated Increase in the Prevalence of Osteoarthritis
  • Increasing Incidence of Sports Injuries

Restraints

  • Risk of Adverse Cardiovascular Events Associated With the Use of Nsaids in Osteoarthritis Treatment

Opportunities

  • Emerging Markets
  • Strategic Collaborations Focused on New Product Development

Challenges

  • Availability of Alternative Non-Drug Pain Management Therapies

Companies Profiled

  • Abbott
  • Anika Therapeutics Inc.
  • Bayer AG
  • Bioventus
  • Eli Lilly
  • Ferring Pharmaceuticals
  • Fidia Farmaceutici S.P.A.
  • Flexion Therapeutics Inc.
  • GlaxoSmithKline PLC
  • Horizon Therapeutics PLC
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • Zimmer Biomet Holdings Inc.

For more information about this report visit https://www.researchandmarkets.com/r/oieyci

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900